期刊文献+

EB病毒LMP2A特异性CTL的体外诱导及分析 被引量:1

Immunological Analysis of EBV LMP2A-Specific CTL Induced by DC Transfected with rVV-LMP2A in vitro
下载PDF
导出
摘要 用EBV LMP2A重组痘苗病毒 (rVV LMP2A )转染人树突状细胞 (DC ) ,转染后的DC分别在第 1、 7、 14天刺激相同MHC背景的T细胞 ,在IL 2作用下诱导LMP2A特异性CTL。用LDH释放法检测CTL杀伤活性 ;流式细胞术 (FACS )检测CTL诱导分化过程中CD3+ 、CD4 + 、CD8+ 、CD5 6 + 等细胞的分群变化 ;RT PCR检测细胞分化过程中FasLmRNA表达 ;生物活性法检测功能性细胞因子IFN γ的分泌。结果显示本法诱导的CTL对靶细胞有特异性杀伤活性 ,第 2次和第 3次DC刺激后杀伤活性有所上升 ;在CTL诱导分化的第 7、 14、 2 1天细胞分群以CD4 + 、CD8+ 细胞为主 ;RT PCR证实所诱导的细胞内有FasLmRNA的表达 ;随细胞培养天数的增加IFN γ分泌增加 ,在第 14天达到较高水平。研究表明重组痘苗病毒载体rVV LMP2A转染的DC刺激T细胞可诱导出EBV LMP2A特异性CTL。 With the help of IL-2,EBV-specific CTL were induced by coculturing EBV-LMP2A recombinant vaccinia virus (rVV-LMP2A) transfected DC with the same donor-derived T cells. Specific cytotoxicity of the CTL was measured by LDH Release Kit. The dynamic alteration of expression of the surface antigen,such as CD3?CD4?CD8 and CD56 were detected by FACS. The level of IFN-γ was measured by biological activity method and the expression of FasL mRNA was detected by RT-PCR.The results showed that the CTL induced in vitro showed specific cytotoxicity to the target cells transfected with LMP2A and the cytotoxicity increased after the second or the third stimulation of DC. The populations of induced cell were composed mainly of CD4 + and CD8 +T cells. Expression of FasL in the induced cell was confirmed by RT-PCR. Secretion of IFN-γ raised as CTL cultured time prolonged but reached a rather high level on day 14. It concludes that strong and functional EBV-specific CTL can be generated by autologous mature DC transfected with rVV-LMP2A. This study may be useful to the applications of CTL-based immunotherapeutic approaches to EBV-associated maliganancies.
出处 《现代免疫学》 CAS CSCD 北大核心 2004年第3期194-197,共4页 Current Immunology
基金 国家自然科学基金资助项目 ( 3 0 170 880 ) 江苏省科委"九五"重大课题基金资助项目 (BJ9810 0 )
关键词 痘苗病毒载体 树突状细胞 EB病毒 潜伏期膜蛋白2A 细胞毒性T细胞 recombinant vaccinia viral vector dendritic cells EBV LMP2A CTL
  • 相关文献

参考文献2

二级参考文献12

  • 1Schneider J,Gilbert SC,Blanchard TJ,et al.Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara[].Nature Medicine.1998
  • 2Zhong L,Piperno AG,Choi Y,et al.Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendertic cells[].European Journal of Immunology.1999
  • 3Carroll MW,Overwijk WW,Chamberlain RS,et al.Highly attenuated modified vaccinia virus Ankara as an effective recombinant vector: a murine tumor model[].Vaccine.1997
  • 4Subklewe M,Chahroudi A,Schmaljohn A,et al.Induction of Epstein-Barr virus cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus[].Blood.1999
  • 5Arthur JF,Butterfield LH,Roth MD,et al.A comparison of gene trandfer methods in human dendritic cells[].Cancer Gene Therapy.1997
  • 6Szabolcs P,Gallardo HF,Ciocon D,et al.Retrovirally transduced human dendritic cells express a normal phenotype and potent T cell stimulatory capacity[].Blood.1997
  • 7Banchereau J,Steinman RM.Dendritic cells and the control of immunity[].Nature.1998
  • 8Lee SP,Tierney RJ,Thomas WA,et al.Conserved CTL Epitopes within EBV Latent Membrane Protein 2: A potential target for CTL-based tumor therapy[].J Immunol.1997
  • 9Baar Joseph.Clinical application of dendritic cell cancer vaccines[].The Oncologist.1999
  • 10Xie Fangyi,Yao Kun,Wang Shengjun,et al.Induction and Identification of dendritic cells from human peripheral mononuclear cells[].Acta Universitatis Medicinalis Nanjing.2001

共引文献13

同被引文献10

  • 1[1]Niedobitek G.Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma[J].Mol Pathol,2000,53:248-254.
  • 2[2]Lopes V,Young LS,Murray PG.Epstein-Barr virus-associated cancers:aetiology and treatment[J].Herpes,2003,10(3):78-82.
  • 3[4]Young LS,Dawson CW,Eliopoulos AG,et al.The expression and function of Epstein-Barr virus encoded latent genes[J].J Clin Pathol:Mol Pathol,2000,53 (5):238-247.
  • 4[5]Leung SF,Tam JS,Chan ATC,et al.Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein Barr virus DNA and anti-Epstein Barr viral capsid antigen IgA antibody[J].Clin Chem,2004,50:339-345.
  • 5[6]Hongsheng W,Matilda WN,Kara LC,et al.EBV latent membrane protein 2A induces autoreactive B cell activation and TLR hypersensitivity[J].J Immunol,2006,177:2793-2802.
  • 6[7]Makoto F,Richard L.Epstein-Barr Virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation[J].J Virol,2005,79:8655-8660.
  • 7[8]Lennette ET,Winberg G,Yadav M,et al.Antibodies to LMP2A/2B in EBV-carrying malignancies[J].Eur J Cancer,1995,31A:1875-1878.
  • 8[10]Thompson MP,Kurzrock R.Epstein-Barr virus and cancer[J].ClinCancer Res,2004,10:803-821.
  • 9[11]Longnecker R,Kieff E.A second Epstein Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1[J].J Virol,1990,64(5):2319-2326.
  • 10[12]Longnecker R,Miller CL,Miao XQ,et al.The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein2 (LMP2) are dispensable for lymphocyte infection and growth transformationinvitro[J].J Virol,1993,67(4):2006-2013.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部